BeiGene
BGNE
#984
Rank
C$28.59 B
Marketcap
$256.40
Share price
1.55%
Change (1 day)
5.01%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Net assets

Net assets on the balance sheet as of September 2024 : C$4.92 Billion

According to BeiGene 's latest financial reports the company has C$4.92 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

BeiGene - Net assets on balance sheet (from 2014 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$C$4.69 B-21.12%
2022-12-31$C$5.94 B-23.9%
2021-12-31$C$7.81 B58.42%
2020-12-31$C$4.93 B286.1%
2019-12-31$C$1.27 B-46.51%
2018-12-31$C$2.38 B177.69%
2017-12-31$C$0.86 B81.39%
2016-12-31$C$0.47 B360.02%
2015-12-31$C$0.10 B244.76%
2014-12-31$C$29.9 M-172.54%
2013-12-31$-C$41.23 Million

Net assets for similar companies or competitors

Company Net assets differencediff. Country
C$8.61 M-99.82%๐Ÿ‡บ๐Ÿ‡ธ USA
C$2.00 B-59.16%๐Ÿ‡บ๐Ÿ‡ธ USA